Table 4.
Rates of recurrence of uveitis by demographic and clinical characteristics
| Recurrence of uveitis | Did not have recurrence | p value | |
|---|---|---|---|
| Gender | |||
| Male | 12/46 (26.1%) | 34/46 (73.9%) | |
| Female | 19/103 (18.4%) | 84/103 (81.6%) | 0.308 |
| Race/ethnicity | |||
| White | 20/92 (21.7%) | 72/92 (78.3%) | Reference |
| Black | 9/34 (26.5%) | 25/34 (73.5%) | 0.574 |
| Other | 2/23 (8.7%) | 21/23 (91.3%) | 0.181 |
| Uveitis type | |||
| Anterior | 13/79 (16.5%) | 66/79 (83.5%) | Reference |
| Intermediate | 10/29 (34.5%) | 19/29 (65.5%) | 0.054 |
| Panuveitis | 6/25 (24.0%) | 19/25 (76.0%) | 0.396 |
| Posterior | 2/15 (13.3%) | 13/15 (86.7%) | 0.772 |
| Unspecified | 0/1 (0%) | 1/1 (100%) | – |
| Length of diagnosis of uveitis, median (range) | 1355 (15–8365) | 1502 (73–19,816) | 0.480 |
| DMARD | |||
| 0 | 21/122 (17.2%) | 101/122 (82.8%) | Reference |
| 1 | 7/20 (35.0%) | 13/20 (65.0%) | 0.075 |
| 2 | 3/7 (42.9%) | 4/7 (57.1%) | 0.099 |
| Combined procedure | |||
| Yes | 13/44 (29.6%) | 31/44 (70.4%) | |
| No | 18/105 (17.1%) | 87/105 (82.9%) | 0.096 |
| Previous CME | |||
| Yes | 14/39 (35.9%) | 25/39 (64.1%) | |
| No | 17/109 (15.6%) | 92/109 (84.4%) | 0.013 |
| History of > 1 episode uveitis | |||
| Yes | 29/119 (24.4%) | 90/119 (75.6%) | |
| No | 2/27 (7.4%) | 25/27 (92.6%) | 0.073 |
| CDE, median (range) | 2.97 (0–14.52) | 3.45 (0–17.93) | 0.780 |
| Length of surgery (min) | |||
| Median (range) | 21 (9–130) | 16 (7–139) | 0.318 |
| Preoperative uveitis treatment plan | |||
| No perioperative steroids | 5/58 (8.6%) | 53/58 (91.4%) | – |
| Only topical drops | 5/14 (35.7%) | 9/14 (64.3%) | – |
| Systemic steroids (IV or oral) a | 10/37 (27.0%) | 27/37 (73.0%) | – |
| STK or intravitreal steroidsa | 4/17 (23.5%) | 13/17 (76.5%) | – |
| Systemic steroids AND STK or intravitreal steroidsa | 7/23 (30.4%) | 16/23 (69.6%) | – |
| Preoperative IOP | |||
| n | 31 | 116 | |
| Mean (SD) | 16.5 (7.8) | 15.1 (5.6) | |
| Median (range) | 15.0 (5–46) | 14.0 (4–42) | 0.302 |
| IOP 1–3 months | |||
| n | 30 | 107 | |
| Mean (SD) | 13.2 (3.4) | 13.4 (3.8) | 0.693 |
| Median (range) | 12.5 (8–22) | 13.0 (4–30) | |
| IOP 4–6 months | |||
| n | 30 | 104 | |
| Mean (SD) | 16.1 (6.4) | 13.0 (3.3) | 0.0009 |
| Median (range) | 14.5 (6–33) | 13.0 (5–22) | |
| logMAR preoperative | |||
| Mean (SD) | 0.796 (0.73) | 0.555 (0.69) | |
| Median (range) | 0.398 (0–3) | 0.301 (0–3) | 0.113 |
| logMAR 6 month follow-up | |||
| Mean (SD) | 0.367 (0.39) | 0.237 (0.44) | |
| Median (range) | 0.176 (− 0.125 to 1.398) | 0.097 (-0.125–2.301) | 0.144 |
| logMAR change | |||
| Mean (SD) | 0.429 (0.53) | 0.318 (0.50) | |
| Median (range) | 0.301 | 0.176 | 0.292 |
aWith or without additional topical steroids